Form 13-F position report

ZEVRA THERAPEUTICS INC

Reported by STATE STREET CORPORATION

ZVRA CUSIP 488445206 Manager CIK 0000093751

Reported 2,050,678 shares, up 368,679 (21.9%) from the prior quarter.

Reported value -6.7%; share count 21.9% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 2,050,678 Quarter-end amount reported
Reported value $22,495,938 Fair value at quarter end
Consecutive quarters held 22 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 4693000
2022-03-31 2775000
2022-06-30 458000
2022-09-30 640000
2022-12-31 471118
2023-03-31 605220
2023-06-30 3031506
2023-09-30 3028054
2023-12-31 4166193
2024-03-31 3962398
2024-06-30 3527309
2024-09-30 5363406
2024-12-31 9779117
2025-03-31 8812345
2025-06-30 10939007
2025-09-30 13573537
2025-12-31 13287286
2026-03-31 14553823
2026-06-30 24119866
2026-09-30 22495938

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ZEVRA THERAPEUTICS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 2,050,678 +368,679 (21.9%) < 0.01% $22,495,938 2026-11-12
Q2 2026 Added 1,681,999 +120,430 (7.7%) < 0.01% $24,119,866 2026-08-07
Q1 2026 Added 1,561,569 +78,613 (5.3%) < 0.01% $14,553,823 2026-05-15
Q4 2025 Added 1,482,956 +55,665 (3.9%) < 0.01% $13,287,286 2026-02-13
Q3 2025 Added 1,427,291 +185,633 (15.0%) < 0.01% $13,573,537 2025-11-14
Q2 2025 Added 1,241,658 +65,110 (5.5%) < 0.01% $10,939,007 2025-08-14
Q1 2025 Added 1,176,548 +3,992 (0.3%) < 0.01% $8,812,345 2025-05-15
Q4 2024 Added 1,172,556 +399,731 (51.7%) < 0.01% $9,779,117 2025-02-14
Q3 2024 Added 772,825 +52,966 (7.4%) < 0.01% $5,363,406 2024-11-14
Q2 2024 Added 719,859 +36,687 (5.4%) < 0.01% $3,527,309 2024-08-14
Q1 2024 Added 683,172 +47,112 (7.4%) < 0.01% $3,962,398 2024-05-15
Q4 2023 Added 636,060 +7,833 (1.2%) < 0.01% $4,166,193 2024-02-14
Q3 2023 Added 628,227 +33,814 (5.7%) < 0.01% $3,028,054 2023-11-14
Q2 2023 Added 594,413 +484,373 (440.2%) < 0.01% $3,031,506 2023-08-14
Q1 2023 Added 110,040 +7,400 (7.2%) < 0.01% $605,220 2023-05-15
Q4 2022 Unchanged 102,640 0 (0.0%) < 0.01% $471,118 2023-02-14
Q3 2022 Unchanged 102,640 0 (0.0%) < 0.01% $640,000 2022-11-15
Q2 2022 Reduced 102,640 -448,975 (-81.4%) < 0.01% $458,000 2022-08-15
Q1 2022 Added 551,615 +12,798 (2.4%) < 0.01% $2,775,000 2022-05-16
Q4 2021 Reduced 538,817 -7,732 (-1.4%) < 0.01% $4,693,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

196 managers reported ZEVRA THERAPEUTICS INC for Q3 2026.

Managers reporting ZEVRA THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 5,562,781 +647,064 < 0.01% $61,023,706 19 qtrs
BlackRock Inc Added 5,135,750 +26,879 < 0.01% $56,339,178 9 qtrs
Woodline Partners LP Added 4,796,864 +11,093 0.16% $52,621,598 11 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 2,627,042 -11,868 < 0.01% $28,818,651 3 qtrs
STATE STREET CORPORATION This report Added 2,050,678 +368,679 < 0.01% $22,495,938 22 qtrs
Nantahala Capital Management LLC Added 1,963,096 +165,620 0.68% $21,535,164 13 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,554,897 +13,961 < 0.01% $17,061,462 23 qtrs
MORGAN STANLEY Added 1,521,035 +317,160 < 0.01% $16,685,753 23 qtrs
D E Shaw & Co Inc Reduced 1,267,686 -39,263 < 0.01% $13,906,515 8 qtrs
DIMENSIONAL FUND ADVISORS LP Added 1,116,541 +157,705 < 0.01% $12,250,421 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 12, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
333,889
Shared
0
None
1,716,789

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.